Kelly Morgan, MS, CGC, on Genetic Testing Education Aiding in Disseminating Information

Video

The MSK expert explained that pre- and post-test educatin on genetic testing could help patients and providers alike to better understand the results.

Pre- and post-test education on genetic testing may help patients disseminate information more easily to their health care providers, according to Kelly Morgan, MS, CGC.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers, which appeared to be effective in educating both patients and providers alike.

“So, in terms of the participant experience, we found satisfaction to be high both after this pre-test education and also after genetic testing. Knowledge was high after the pre-test education, which was very important from our perspective to make sure our participants were able to adequately receive the information they need to make a decision like this,” said Morgan, a genetic counselor at Memorial Sloan Kettering Cancer Center.

In an interview with CancerNetwork, Morgan explained how these results can affect health care providers’ knowledge of genetic testing moving forward.

Transcription:

From our perspective, we really see this model as a way to more effectively disseminate information. So whether that be to patients but also importantly to their doctors. So you're absolutely right in terms of having a multidisciplinary team and the more that we can engage not only a patient, but their community and their providers to build the biggest sort of network of resources we can, I think that's important. And these digital tools I think, can create a centerpiece for patients and their physicians to come together and both learn

Related Videos
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Related Content